MGMT in colorectal cancer: a promising component of personalized treatment

[1]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[2]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[3]  S. Kakar,et al.  Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma , 2012, Modern Pathology.

[4]  A. Figer,et al.  Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Shuji Ogino,et al.  MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers , 2011, Cancer Causes & Control.

[6]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[7]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[8]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Barrett,et al.  Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Matsubara,et al.  Methylation pattern of the O6‐methylguanine‐DNA methyltransferase gene in colon during progressive colorectal tumorigenesis , 2008, International journal of cancer.

[12]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Timothy C Ryken,et al.  Management of malignant glioma: steady progress with multimodal approaches. , 2006, Neurosurgical focus.

[14]  Jang-Yang Chang,et al.  DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors , 2006, Journal of Pharmacology and Experimental Therapeutics.

[15]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[16]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[17]  R. Stupp,et al.  New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. , 2006, Neurosurgical focus.

[18]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[19]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[20]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  設楽 兼司,et al.  胃癌におけるO^6-Methylguanine-DNA Methyltransferase(MGMT)発現 , 2002 .

[22]  B. Leggett,et al.  Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. , 2001, Cancer research.

[23]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[25]  M. Valentine,et al.  Chromosomal localization of human O6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. , 1992, Mutagenesis.

[26]  M. Dolan,et al.  Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. , 1991, Cancer research.

[27]  M. Dolan,et al.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Leyland-Jones,et al.  Biochemistry of azacitidine: a review. , 1987, Cancer treatment reports.

[29]  Peter A. Jones.  Altering gene expression with 5-azacytidine , 1985, Cell.

[30]  Taylor Sm,et al.  5-Azacytidine, DNA methylation, and differentiation. , 1984 .